View Older Stories View More Recent Stories

Jun 24, 2021 08:30AM Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Jun 24, 2021 08:30AM Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration
Jun 10, 2021 02:18PM Prothena to Participate in JMP Securities Life Sciences Conference on June 16
Jun 10, 2021 02:18PM Prothena to Participate in JMP Securities Life Sciences Conference on June 16
May 20, 2021 04:24PM Prothena Corp. (PRTA) Adds Sanjiv Patel to Board
May 20, 2021 04:05PM Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
May 20, 2021 04:05PM Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
May 11, 2021 04:05PM Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
May 11, 2021 04:05PM Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
May 11, 2021 05:49AM Prothena Corp. (PRTA) Secures $60M Milestone from Roche for First Patient Dosing in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
May 10, 2021 04:05PM Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
May 10, 2021 04:05PM Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease
May 7, 2021 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2021 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2021 04:05PM Prothena to Report First Quarter 2021 Financial Results on May 11th
May 4, 2021 04:05PM Prothena to Report First Quarter 2021 Financial Results on May 11th
Apr 19, 2021 05:52AM Prothena Corp. (PRTA) Highlights Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Apr 18, 2021 03:05PM Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Apr 18, 2021 03:05PM Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Apr 7, 2021 04:05PM Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 7, 2021 04:05PM Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 8, 2021 04:05PM Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
Mar 8, 2021 04:05PM Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
Feb 24, 2021 05:06PM Prothena Corp. (PRTA) Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Feb 24, 2021 04:05PM Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Feb 24, 2021 04:05PM Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Feb 11, 2021 08:00AM Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
Feb 11, 2021 08:00AM Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
Feb 5, 2021 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 5, 2021 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 4, 2021 04:05PM Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
Feb 4, 2021 04:05PM Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
Feb 1, 2021 04:16PM Prothena Corp. (PRTA) Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
Feb 1, 2021 04:15PM Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
Feb 1, 2021 04:15PM Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
Dec 9, 2020 08:00AM Prothena Corp. (PRTA) Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004
Dec 9, 2020 08:00AM Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
Dec 9, 2020 08:00AM Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
Dec 4, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 4, 2020 04:05PM Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2020 04:05PM Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
Nov 4, 2020 04:05PM Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
Nov 4, 2020 08:30AM Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
Nov 4, 2020 08:30AM Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
Oct 28, 2020 04:05PM Prothena to Report Third Quarter 2020 Financial Results on November 4
Oct 28, 2020 04:05PM Prothena to Report Third Quarter 2020 Financial Results on November 4
Oct 21, 2020 09:27AM Pre-Open Stock Movers 10/21: (ASTC) (SNAP) (CALX) Higher; (GSX) (NAVI) (NFLX) Lower (more...)
Oct 20, 2020 05:33PM After-Hours Stock Movers 10/20: (ASTC) (SNAP) (PRTA) Higher; (NAVI) (NFLX) (APTX) Lower (more...)
Oct 20, 2020 04:15PM Roche and Prothena (PRTA) will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
Oct 20, 2020 04:05PM Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
View More Recent Stories View Older Stories